W J Fokkens, V Backer, V J Lund, P J Barnes, M Bernal-Sprekelsen, L Bjermer, E de Corso, D M Conti, M E Cornet, Z Diamant, R Djukanovic, M Gaga, P Gevaert, J K Han, C Hopkins, G Joos, B N Landis, S Lau, S E Lee, J Mullol, A T Peters, G K Scadding, S Schneider, B Senior, I D Pavord, S Quirce, D Ryan, M E Wechsler, P W Hellings
{"title":"Pocket guide: biologics in upper and lower airways in adults.","authors":"W J Fokkens, V Backer, V J Lund, P J Barnes, M Bernal-Sprekelsen, L Bjermer, E de Corso, D M Conti, M E Cornet, Z Diamant, R Djukanovic, M Gaga, P Gevaert, J K Han, C Hopkins, G Joos, B N Landis, S Lau, S E Lee, J Mullol, A T Peters, G K Scadding, S Schneider, B Senior, I D Pavord, S Quirce, D Ryan, M E Wechsler, P W Hellings","doi":"10.4193/Rhin24.510","DOIUrl":null,"url":null,"abstract":"<p><p>The introduction of biologics for the treatment of severe upper and lower (type 2) airway inflammation has been a gamechanger in the management of these diseases. Biologics are injectable medications targeting different molecules relevant in (type 2) inflammation in patients with severe (type 2) airway diseases, like asthma, eosinophilic chronic obstructive pulmonary disease (COPD), chronic rhinosinusitis (CRS) and those who remain uncontrolled despite regular treatment (1-3). After the phase 3 trials, showing significant impact on symptoms, quality of life and interventions like surgery (for the upper airways) and exacerbations needing hospitalisation (for the lower airways), biologics are now used in daily practice in many parts of the world (4, 5). This pocket guide is aimed at all specialists treating adult patients with severe airway disease.</p>","PeriodicalId":21361,"journal":{"name":"Rhinology","volume":" ","pages":""},"PeriodicalIF":4.8000,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Rhinology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4193/Rhin24.510","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OTORHINOLARYNGOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
The introduction of biologics for the treatment of severe upper and lower (type 2) airway inflammation has been a gamechanger in the management of these diseases. Biologics are injectable medications targeting different molecules relevant in (type 2) inflammation in patients with severe (type 2) airway diseases, like asthma, eosinophilic chronic obstructive pulmonary disease (COPD), chronic rhinosinusitis (CRS) and those who remain uncontrolled despite regular treatment (1-3). After the phase 3 trials, showing significant impact on symptoms, quality of life and interventions like surgery (for the upper airways) and exacerbations needing hospitalisation (for the lower airways), biologics are now used in daily practice in many parts of the world (4, 5). This pocket guide is aimed at all specialists treating adult patients with severe airway disease.
期刊介绍：
Rhinology serves as the official Journal of the International Rhinologic Society and is recognized as one of the journals of the European Rhinologic Society. It offers a prominent platform for disseminating rhinologic research, reviews, position papers, task force reports, and guidelines to an international scientific audience. The journal also boasts the prestigious European Position Paper in Rhinosinusitis (EPOS), a highly influential publication first released in 2005 and subsequently updated in 2007, 2012, and most recently in 2020.
Employing a double-blind peer review system, Rhinology welcomes original articles, review articles, and letters to the editor.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
